Therapeutic drug monitoring of nelfinavir in pregnancy: A case report

Therapeutic Drug Monitoring

Volumn 26, Issue 5, 2004, Pages 576-578

  Burger, David M ^a   Grintjes, Karin J T ^a   Lotgering, Fred K ^a   Koopmans, Peter P ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

HIV; Nelfinavir; Pregnancy; Therapeutic drug monitoring

Indexed keywords

INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; STAVUDINE;

ADULT; ARTICLE; CASE REPORT; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG MONITORING; DRUG RESPONSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; PREGNANCY; PRIORITY JOURNAL; VIRUS LOAD;

ADULT; DRUG MONITORING; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; NELFINAVIR; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY OUTCOME; VIRAL LOAD;

EID: 4744371341     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200410000-00017     Document Type: Article

References (12)

1. Burger DM, Aarnoutse RE, Hugen PW. Pros and cons of therapeutic drug monitoring of antiretroviral agents. Curr Opin Infect Dis. 2002;15:17-22.
2. Aarnoutse RE, Schapiro JM, Boucher CA, et al. Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs? Drugs. 2003;63:741-753.
3. Acosta EP, Gerber JG. Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Res Hum Retroviruses. 2002;18:825-834.
4. Anonymous. Optimising TDM in HIV clinical care. A practical guide to performing therapeutic drug monitoring (TDM) for antiretroviral agents. Available: http://www.HIVpharmacology.com. Last visited at September 12, 2003.
5. Burger DM, Hugen PW, Aarnoutse RE, et al. Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations. Ther Drug Monit. 2003;25:73-80.
6. Ensom MHH, Davis GA, Cropp CD, et al. Clinical pharmacokinetics in the 21st century: does the evidence support definitive outcomes? Clin Pharmacokinet. 1998;34:265-279.
7. Hoetelmans RMW, Reijers MHE, Weverling GJ, et al. The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy. AIDS. 1998;12:F111-F115.
8. Pellegrin I, Breilh D, Montestruc F, et al. Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study). AIDS. 2002;16:1331-1340.
9. Powderly WG, Saag MS, Chapman S, et al. Predictors of optimal virological response to potent antiretroviral therapy. AIDS. 1999;13:1873-1880.
10. Burger D, Hugen P, Reiss P, et al. Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS. 2003;17:1157-1165.
11. Wit F, Nellen J, Bergshoeff A, et al. Plasma nelfinavir concentrations are significantly lower in pregnancy. Antivir Ther. 2003;8:S214-S215.
12. Angel JB, Khaliq Y, Monpetit ML, et al. An argument for routine therapeutic drug monitoring of HIV-1 protease inhibitors during pregnancy. AIDS. 2001;15:417-419.